Cargando…
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patients. mCRPC patients receiving second-line cabazitaxe...
Autores principales: | Oh, William K., Miao, Raymond, Vekeman, Francis, Sung, Jennifer, Cheng, Wendy Y., Gauthier-Loiselle, Marjolaine, Dhawan, Ravinder, Duh, Mei Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550521/ https://www.ncbi.nlm.nih.gov/pubmed/28795333 http://dx.doi.org/10.1007/s12032-017-1014-2 |
Ejemplares similares
-
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011) -
Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021) -
Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic
Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017) -
Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015) -
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)